Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Could High Profile Combo Be Allergan/Novartis Answer To Late-Stage NASH Programs?

Apr 19 2017

• By Sukaina Virji

Liver anatomy

Related Content

Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study

Jul 25 2016

In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner

Dec 20 2016

Intercept Boosts NASH Commercial Potential Via NICE Rare Disease Move

Mar 02 2017

Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground

Jan 13 2017

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn

Sep 21 2016

Related Companies

Novartis AG

Allergan plc

Allergan plc

Intercept Pharmaceuticals, Inc.

Genfit SA

Gilead Sciences, Inc.

Additional Topics

Research & Development Companies Liver & Hepatic BioPharmaceutical

More from R&D

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.